Reaction
Application Site Burn reporting signals
As of the last recalculation, Application Site Burn appears in 4,888 FAERS reports alongside 37 co-occurring drug terms. The strongest observed disproportionality signal is BUPRENORPHINE (PRR 37.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Buprenorphine | 697 | 37.2 | 37.5 |
| Crisaborole | 62 | 27.9 | 28.0 |
| Nicotine | 165 | 17.9 | 18.0 |
| Oxybutynin | 98 | 14.5 | 14.6 |
| Glycerin, Lidocaine | 44 | 13.5 | 13.5 |
| Docosanol | 46 | 13.5 | 13.5 |
| Methylphenidate | 82 | 12.2 | 12.3 |
| Minoxidil Foam 5% (Womens) | 93 | 12.2 | 12.2 |
| Miconazole Nitrate | 24 | 11.8 | 11.8 |
| Nicotine Polacrilex | 96 | 10.9 | 10.9 |
| Estradiol | 209 | 10.7 | 10.7 |
| Minoxidil | 102 | 9.9 | 9.9 |
| Nicotine Polacrilex Mini | 33 | 9.4 | 9.4 |
| Nicotine Polarilex | 33 | 9.4 | 9.4 |
| Rotigotine | 25 | 7.4 | 7.4 |
| Lidocaine, Menthol | 79 | 6.9 | 6.9 |
| Clonidine | 73 | 6.1 | 6.2 |
| Estradiol Gel 0.1% | 61 | 5.8 | 5.8 |
| Estradiol Transdermal | 61 | 5.8 | 5.8 |
| Progesterone | 23 | 4.3 | 4.3 |
| Sumatriptan | 38 | 4.3 | 4.3 |
| Granisetron | 10 | 4.1 | 4.1 |
| Carisoprodol | 18 | 4.0 | 4.0 |
| Diclofenac Potassium | 9 | 3.6 | 3.6 |
| Sumatriptan Succinate | 20 | 3.4 | 3.4 |
| Amlodipine Besylate And Benazepril Hydrochloride | 7 | 3.2 | 3.2 |
| Butalbital, Acetaminophen, And Caffeine | 8 | 3.2 | 3.2 |
| Tretinoin | 6 | 3.2 | 3.2 |
| Rizatriptan Benzoate | 7 | 2.9 | 2.9 |
| Thyroid, Porcine | 7 | 2.8 | 2.8 |
| Multivitamin | 27 | 2.3 | 2.3 |
| Acetaminophen, Aspirin (Nsaid) And Caffeine | 8 | 2.0 | 2.0 |
| Acetaminophen, Aspirin, And Caffeine | 8 | 1.6 | 1.6 |
| Vilazodone Hydrochloride | 3 | 1.4 | 1.4 |
| Salicylic Acid | 12 | 1.0 | 1.0 |
| Tapentadol Hydrochloride | 5 | 0.6 | 0.6 |
| Adapalene | 17 | 0.4 | 0.4 |